New
First patient enrolled in AVITA Therapeutic’s study in Miami earlier this week. The prospective study is evaluating the RECELL system for repigmentation of patients with stable vitiligo, meaning they have not had new vitiligo lesions or lesions that have expanded for at least one year.
AVITA’s technology creates an autologous suspension from a piece of the patient's own normal skin in under 30 minutes, to spray pigment-producing cells onto vitiligo lesion.
The company is about to begin two multi-center clinical trials in the USA (details 1 and details 2)
For more information, please contact: Elizabeth Kirshner at 661-367-9180 or ekirshner@avitamedical.com
FAQOther Questions
- Awareness Days Similar to World Vitiligo Day
World Vitiligo Day, celebrated annually on June 25 since 2012, is a significant event dedicated to raising awareness about vitiligo and supporting those affected by the conditio...
- Is there a traditional medicine to treat vitiligo?
Traditional remedies can play a supportive role in managing chronic, metabolic, and stress-related conditions—particularly early in the disease process, before significant tissu...
- How to get insurance coverage for vitiligo treatments?
Getting insurance coverage for vitiligo treatments can be challenging, but there are several steps you can take to improve your chances For a more in-depth look, check out our ...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.